caf676a4ac
- Source: inbox/queue/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
2.3 KiB
2.3 KiB
| type | entity_type | name | founded | headquarters | founders | status | website | domain | tags | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| entity | company | Mark Cuban Cost Plus Drug Company | 2022 | Dallas, TX | Mark Cuban, Alex Oshmyansky | active | costplusdrugs.com | health |
|
Mark Cuban Cost Plus Drug Company
Overview
Cost Plus Drug Company is a direct-to-consumer pharmacy founded in 2022 by Mark Cuban and Alex Oshmyansky. The company operates on a transparent pricing model: acquisition cost + 15% markup + $3 pharmacy fee + $5 shipping, offering over 2,300 medications (primarily generics).
Business Model
Pricing Structure:
- Acquisition cost + 15% fixed fee
- No insurance intermediation for direct-to-consumer sales
- Transparent pricing published online
Product Portfolio:
- 2,300+ medications (mostly generics)
- Expanding into biosimilar portfolio
- Pursuing US manufacturing expansion with generic drug fee waivers
Distribution Strategy:
- Partnership with Humana CenterWell Pharmacy for employer prescription solutions (2025)
- Combines Cost Plus pass-through pricing with CenterWell distribution infrastructure
- Dependent on incumbent partnerships rather than independent distribution
Market Position
Competitive Context:
- Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) control ~80% of US prescription claims
- Cost Plus operates as challenger model coexisting with incumbents
- Growing market share but partnering with incumbents (Humana) rather than displacing PBMs
Political Role:
- Mark Cuban testified at congressional hearings on PBM practices
- Supported FTC investigations into PBM business practices
- Functions as political/narrative pressure vehicle even with small market share
Limitations
- Primarily generic drugs — does not address branded/biologic drugs where margins are highest
- No owned distribution infrastructure — dependent on partnerships
- No clinical services layer — drug pricing tool, not care delivery model
- Has not achieved meaningful market share in specialty drugs where margin extraction is concentrated
Timeline
- 2022 — Company founded by Mark Cuban and Alex Oshmyansky
- 2025-11 — Partnership announced with Humana CenterWell Pharmacy for employer prescription solutions
- 2026 — Expanding biosimilar portfolio and pursuing US manufacturing expansion